Gilead, Merck Report 48-Week Phase 3 Success for Once-Weekly HIV Pill
Center50%
Right25%
Far Right25%
Gilead, Merck Announce Positive Phase 3 Results for Once-Weekly Oral HIV Treatment Islatravir/LenacapavirMerck, Gilead once-weekly HIV tablet meets Phase 3 goal | MRK Stock NewsGilead and Merck pipeline update reveals promise in HIV and pressure in oncology - PharmaDeviceNewsMerck, Gilead share positive phase 3 results from combination HIV pill | Seeking AlphaMerck, Gilead serve 'sweet and sour' spread after HIV win, cancer stumble - BioSpaceCantor Fitzgerald reiterates Gilead stock rating on HIV trial data By Investing.cominvestors.gilead.com1d ago Gilead Sciences, Inc. - Gilead and Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly HIV TreatmentGilead Sciences, Inc. And Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, An Oral Once-Weekly HIV Treatment | MarketScreenerZacks Investment Research1d ago Gilead, Merck Report Positive Phase III HIV Study Data, End NSCLC Study - June 9, 2026 - Zacks.comNew Long Acting Oral HIV Regimen Meets Primary Endpoints In Phase 3 Trials